Under the if-all-adhere estimand, participants on CagriSema achieved approximately 15.7% weight reduction at week 68, compared with approximately 3% for placebo
Tracked, insured, delivered in 23 business days
American Academy of Pediatrics Committee on Fetus and Newborn
Human obesity studies were also conducted during pharmaceutical development, but the largest reported placebo-controlled study did not demonstrate a statistically significant weight-loss benefit, and development for obesity was discontinued
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material